| References: |
As a novel, orally available, selective tyrosine kinase inhibitor of the Trk family of tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and ALK proteins, entrectinib is designed as a targeted therapeutic candidate to treat patients with cancers that harbor activating alterations to TrkA, TrkB, TrkC, ROS1 or ALK. Entrectinib has demonstrated in vivo antitumor activity against various TrkA, ROS1 or ALK-driven mouse xenograft models of different human cancers, and has demonstrated oral bioavailability and been observed to efficiently cross the blood brain barrier in three animal species. For the detailed information of Entrectinib (RXDX-101), the solubility of Entrectinib (RXDX-101) in water, the solubility of Entrectinib (RXDX-101) in DMSO, the solubility of Entrectinib (RXDX-101) in PBS buffer, the animal experiment (test) of Entrectinib (RXDX-101), the cell expriment (test) of Entrectinib (RXDX-101), the in vivo, in vitro and clinical trial test of Entrectinib (RXDX-101), the EC50, IC50,and affinity,of Entrectinib (RXDX-101), For the detailed information of Entrectinib (RXDX-101), the solubility of Entrectinib (RXDX-101) in water, the solubility of Entrectinib (RXDX-101) in DMSO, the solubility of Entrectinib (RXDX-101) in PBS buffer, the animal experiment (test) of Entrectinib (RXDX-101), the cell expriment (test) of Entrectinib (RXDX-101), the in vivo, in vitro and clinical trial test of Entrectinib (RXDX-101), the EC50, IC50,and affinity,of Entrectinib (RXDX-101), Please contact DC Chemicals. |
